Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 300639.SZ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 300639.SZ and 80,000+ other tickers.
See exactly how 300639.SZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 300639.SZ and 80,000+ other tickers.
Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. It also provides on-site technical training and after-sales technical service support. The company was founded by Qiao Zhong Guan on June 13, 2003 and is headquartered in Chaozhou, China.
No recent news available.